United Therapeutics (NASDAQ:UTHR) CEO Sells $5,108,530.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $537.74, for a total transaction of $5,108,530.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $21,785,460.62. This represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

United Therapeutics Stock Up 1.1%

Shares of NASDAQ UTHR opened at $544.33 on Wednesday. United Therapeutics Corporation has a twelve month low of $272.12 and a twelve month high of $609.35. The firm has a fifty day simple moving average of $563.19 and a 200 day simple moving average of $524.62. The company has a market capitalization of $23.11 billion, a PE ratio of 20.09, a P/E/G ratio of 1.75 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same period last year, the company posted $6.63 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. As a group, equities analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on UTHR shares. HC Wainwright raised their target price on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research note on Tuesday, March 31st. Bank of America increased their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada dropped their target price on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $619.42.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC grew its stake in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP lifted its holdings in shares of United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of United Therapeutics by 29.9% in the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Janus Henderson Group PLC grew its position in United Therapeutics by 8.9% in the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock valued at $514,016,000 after purchasing an additional 70,829 shares during the period. Finally, Darwin Global Management Ltd. acquired a new stake in United Therapeutics in the 3rd quarter valued at $317,617,000. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.